# Supplementary Materials

## Supplementary Table 1: Individual participant characteristics

| ID | Sex   | HBV co-infection status | ART status | Cells used | HIV sequences obtained | Intact HIV sequences obtained | Inversions | Large Internal Deletions | Early Stop Codon | Frame-shift | Hyper-mutation | Cis-acting Mutation | Average p-distance of genetically-intact |
|----|-------|--------------------------|------------|------------|------------------------|-----------------------------|------------|--------------------------|----------------|-------------|----------------|------------------------|------------------------------------------|
| 1  | Male  | Co-infection             | pre-therapy| 118833     | 68                     | 7                           | 2                       | 52                      | 0              | 0           | 7             | 0                      | 0.01                                     |
| 2  | Male  | Co-infection             | pre-therapy| 11260      | 19                     | 4                           | 1                       | 13                      | 0              | 0           | 1             | 0                      | N/A                                     |
| 3  | Male  | Co-infection             | pre-therapy| 15087      | 63                     | 27                          | 0                       | 30                      | 0              | 2           | 3             | 1                      | 0.016                                   |
| 4  | Male  | Co-infection             | pre-therapy| 56835      | 28                     | 9                           | 0                       | 19                      | 0              | 0           | 0             | 0                      | 0.01                                     |
| 5  | Male  | Co-infection             | pre-therapy| 73476      | 53                     | 19                          | 0                       | 29                      | 1              | 2           | 1             | 1                      | 0.012                                   |
| 6  | Male  | Co-infection             | pre-therapy| 16012      | 73                     | 22                          | 2                       | 40                      | 1              | 2           | 6             | 0                      | 0.01                                     |
| 7  | Female| Co-infection             | pre-therapy| 45533      | 57                     | 16                          | 2                       | 37                      | 1              | 0           | 1             | 0                      | 0.019                                   |
| 8  | Male  | Co-infection             | pre-therapy| 52162      | 57                     | 21                          | 1                       | 22                      | 1              | 2           | 10            | 0                      | 0.006                                   |
| 9  | Male  | Co-infection             | pre-therapy| 31578      | 67                     | 16                          | 0                       | 49                      | 0              | 1           | 1             | 0                      | 0.013                                   |
| 10 | Male  | Co-infection             | pre-therapy| 213863     | 38                     | 16                          | 3                       | 15                      | 0              | 1           | 2             | 1                      | 0.052                                   |
| 11 | Male  | Co-infection             | pre-therapy| 18718      | 70                     | 24                          | 0                       | 42                      | 2              | 2           | 0             | 0                      | 0.018                                   |
| 12 | Female| Co-infection             | pre-therapy| 55343      | 62                     | 26                          | 0                       | 28                      | 0              | 1           | 6             | 1                      | 0.002                                   |
| 13 | Male  | Co-infection             | pre-therapy| 22614      | 58                     | 38                          | 1                       | 13                      | 3              | 2           | 1             | 0                      | 0.013                                   |
| 14 | Male  | Co-infection             | pre-therapy| 157511     | 34                     | 15                          | 1                       | 16                      | 1              | 1           | 0             | 0                      | 0.008                                   |
| 15 | Male  | Co-infection             | pre-therapy| 26674      | 70                     | 33                          | 0                       | 34                      | 0              | 1           | 2             | 0                      | 0.022                                   |
| 16 | Female| Co-infection             | pre-therapy| 34347      | 58                     | 45                          | 0                       | 9                       | 0              | 1           | 3             | 0                      | 0.012                                   |
| 17 | Male  | Co-infection             | pre-therapy| 137126     | 44                     | 20                          | 1                       | 20                      | 1              | 1           | 1             | 0                      | 0.007                                   |
| 18 | Male  | Co-infection             | pre-therapy| 52258      | 60                     | 25                          | 0                       | 33                      | 0              | 1           | 1             | 0                      | 0.016                                   |
| 19 | Female| Co-infection             | pre-therapy| 77808      | 65                     | 20                          | 2                       | 37                      | 0              | 1           | 4             | 1                      | 0.013                                   |
| 20 | Male  | Co-infection             | pre-therapy| 76273      | 66                     | 25                          | 0                       | 37                      | 1              | 1           | 2             | 0                      | 0.003                                   |
| 21 | Male  | Co-infection             | pre-therapy| 58124      | 21                     | 3                           | 1                       | 16                      | 0              | 0           | 0             | 1                      | N/A                                     |
| 22 | Male  | Co-infection             | on-therapy | 213644     | 48                     | 0                            | 1                       | 37                      | 0              | 0           | 9             | 1                      | N/A                                     |
| 23 | Male  | Co-infection             | on-therapy | 121311     | 48                     | 2                            | 2                       | 38                      | 0              | 0           | 5             | 1                      | N/A                                     |
| 24 | Male  | Co-infection             | on-therapy | 29679      | 54                     | 23                           | 1                       | 26                      | 1              | 1           | 2             | 0                      | N/A                                     |
| 25 | Male  | Co-infection             | on-therapy | 263617     | 52                     | 2                            | 2                       | 44                      | 0              | 1           | 2             | 1                      | N/A                                     |
| 26 | Male  | Co-infection             | on-therapy | 258979     | 28                     | 1                            | 1                       | 22                      | 0              | 0           | 3             | 1                      | N/A                                     |
| 27 | Male  | Co-infection             | on-therapy | 405991     | 38                     | 2                            | 5                       | 31                      | 0              | 0           | 0             | 0                      | N/A                                     |
| 28 | Female| HIV mono-infection       | pre-therapy| 80490      | 50                     | 12                           | 0                       | 29                      | 0              | 0           | 4             | 5                      | 1.5                                     |
| 29 | Female| HIV mono-infection       | on-therapy | 324818     | 52                     | 2                            | 1                       | 33                      | 0              | 0           | 14            | 2                      | N/A                                     |
| 30 | Male  | HIV mono-infection       | pre-therapy| 38831      | 38                     | 20                           | 0                       | 17                      | 0              | 0           | 1             | 0                      | 0.3                                     |
| 31 | Male  | HIV mono-infection       | on-therapy | 198157     | 49                     | 3                            | 2                       | 38                      | 0              | 0           | 3             | 3                      | N/A                                     |
|   |   | HIV mono-infection |   |   |   |   |   |   |   |   |   |   |   |
|---|---|-------------------|---|---|---|---|---|---|---|---|---|---|---|
| C | Female | HIV mono-infection | pre-therapy | 153377 | 43 | 12 | 1 | 29 | 0 | 0 | 1 | 0 | 0.3 |
| C | Female | HIV mono-infection | on-therapy | 379985 | 49 | 6 | 2 | 24 | 0 | 0 | 13 | 4 | N/A |
| D | Male | HIV mono-infection | pre-therapy | 141479 | 31 | 12 | 1 | 16 | 1 | 1 | 0 | 0 | 0.3 |
| D | Male | HIV mono-infection | on-therapy | 362589 | 40 | 5 | 4 | 25 | 0 | 1 | 5 | 0 | N/A |
| E | Male | HIV mono-infection | pre-therapy | 551027 | 47 | 27 | 1 | 18 | 0 | 0 | 1 | 0 | 0.6 |
| E | Male | HIV mono-infection | on-therapy | 75093 | 64 | 8 | 2 | 44 | 0 | 0 | 9 | 1 | N/A |
| F | Male | HIV mono-infection | pre-therapy | 153376 | 23 | 5 | 0 | 17 | 1 | 0 | 0 | 0 | 1.4 |
| F | Male | HIV mono-infection | on-therapy | 379984 | 52 | 2 | 5 | 39 | 0 | 0 | 5 | 1 | N/A |
Supplementary Figure 1: Comparison of the age (A), CD4+ T cell counts (B) and HIV RNA levels (C) between the HIV-HBV co-infected and HIV mono-infected cohort. Mann-Whitney tests were performed to determine whether these cohorts differed significantly across these three parameters. Spearman correlation tests on the relationship between the age of the individual and D) the infection frequency of genetically-intact HIV proviruses and E) the genetic diversity of genetically-intact HIV proviruses sequenced from that individual. F) Mann-Whitney test comparing the infection frequency of genetically-intact HIV proviruses between male and female participants, regardless of HBV infection status. G) Mann-Whitney test comparing the genetic diversity of genetically-intact HIV proviruses between male and female participants, regardless of HBV infection status.